$SNY

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

Sanofi shareholders approve Belén Garijo as CEO effective May 1, 2026, authorizing €4.12 dividend and welcoming Orange's Christel Heydemann to board.

Sanofi's AGM appoints physician Belén Garijo as CEO effective May 1, 2026, approves €4.12 dividend and welcomes Orange's Heydemann to board.

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.

Costco, Sanofi, and SAP announce double-digit dividend increases—13%, 19%, and 15% respectively—reflecting mega-cap confidence in cash generation and shareholder commitment.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

Sanofi launches multi-tranche bond offering with April-June issuance window, HSBC-led stabilization, and maturities spanning 2029-2037.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Sanofi's Dupixent gains FDA approval for pediatric urticaria as Q1 earnings beat expectations with 30.8% drug growth at $12.31B sales.

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Sanofi seeks FDA approval for first on-body injector cancer therapy; decision extended to July 2026. Tzield pediatric indication also expanded.

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

FDA approves $SANF's Tzield for children ages 1+ with stage 2 type 1 diabetes, expanding from prior 8+ restriction. First disease-modifying therapy for autoimmune condition.

FDA approves Sanofi's Tzield for children as young as one with type 1 diabetes, marking first disease-modifying therapy for this young cohort.

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.

France's 2026 equities expected to concentrate on luxury, pharma, banking, and consumer staples giants despite moderate domestic growth.